Verastem (VSTM) Change in Cash (2011 - 2026)
Verastem (VSTM) posted quarterly Change in Cash of -$39.4 million for Q1 2026, down 237.17% year-over-year from $28.8 million in Q1 2025, and down 158.62% quarter-over-quarter from $67.3 million in Q4 2025.
Analysis
Verastem (VSTM) Change in Cash (2011 - 2026) Analysis & Trends
Verastem's Change in Cash history runs 16 years deep, the most recent figure standing at -$39.4 million for Q1 2026.
- In Q1 2026, Change in Cash fell 237.17% year-over-year to -$39.4 million; the TTM figure through Mar 2026 stood at $48.0 million (up 36.25% YoY), while the FY2025 annual figure was $116.2 million, up 1063.7% from the prior year.
- Change in Cash for Q1 2026 stood at -$39.4 million, down from $67.3 million in the prior quarter.
- The five-year high for Change in Cash was $85.6 million in Q2 2023, with the low at -$87.6 million in Q3 2023.
- The 5-year median for Change in Cash is $15.2 million (2022), against an average of $8.5 million.
- The sharpest annual moves came in 2023 and 2025: Change in Cash slumped 676.46% in 2023, then jumped 4492.63% in 2025.
- Verastem's Change in Cash stood at -$3.6 million in 2022, then plunged by 392.65% to -$17.7 million in 2023, then plunged by 37.68% to -$24.4 million in 2024, then jumped by 376.24% to $67.3 million in 2025, then plunged by 158.62% to -$39.4 million in 2026.
- Business Quant data shows VSTM's Change in Cash at -$39.4 million in Q1 2026, $67.3 million in Q4 2025, and -$26.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Verastem | 815.85 Mn | 679.49 Mn | 36.32 Mn | -29.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.20 Mn |
| Mar 31, 2026 | -39.44 Mn |
| Dec 31, 2025 | 67.28 Mn |
| Sep 30, 2025 | -26.62 Mn |
| Jun 30, 2025 | 46.75 Mn |
| Mar 31, 2025 | 28.75 Mn |
| Dec 31, 2024 | -24.36 Mn |
| Sep 30, 2024 | 29.80 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | -17.69 Mn |
| Sep 30, 2023 | -87.56 Mn |
| Jun 30, 2023 | 85.58 Mn |
| Mar 31, 2023 | 22.96 Mn |
| Dec 31, 2022 | -3.59 Mn |
| Sep 30, 2022 | 15.19 Mn |
| Jun 30, 2022 | 17.26 Mn |
| Mar 31, 2022 | 25.44 Mn |
| Dec 31, 2021 | -3.06 Mn |
| Sep 30, 2021 | -658,000.00 |